JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Additional Paid-In Capital: ฿722.9 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:JSP-R JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP-R
82 GF Score
Price ฿1.75
GF Value ฿2.18
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is JSP Pharmaceutical Manufacturing (Thailand) PCL Additional Paid-In Capital?

JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP-R +0.32% 82 Additional Paid-In Capital is ฿722.9 Mil as of Jun. 2026. GuruFocus rates BKK:JSP-R with a GF Score™ of 82/100 and a GF Value™ of ฿2.18 (Modestly Undervalued). The stock has 7 warning signs investors should review.


JSP Pharmaceutical Manufacturing (Thailand) PCL's quarterly additional paid-in capital stayed the same from Dec. 2025 (฿722.9 Mil) to Mar. 2026 (฿722.9 Mil) and stayed the same from Mar. 2026 (฿722.9 Mil) to Jun. 2026 (฿722.9 Mil).

JSP Pharmaceutical Manufacturing (Thailand) PCL's annual additional paid-in capital increased from Dec. 2023 (฿772.5 Mil) to Dec. 2024 (฿772.5 Mil) but then declined from Dec. 2024 (฿772.5 Mil) to Dec. 2025 (฿722.9 Mil).

JSP Pharmaceutical Manufacturing (Thailand) PCL Additional Paid-In Capital Related Terms

JSP Pharmaceutical Manufacturing (Thailand) PCL Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for JSP Pharmaceutical Manufacturing (Thailand) PCL's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JSP Pharmaceutical Manufacturing (Thailand) PCL Additional Paid-In Capital Chart

JSP Pharmaceutical Manufacturing (Thailand) PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial 733.46 733.46 772.49 772.53 722.93

JSP Pharmaceutical Manufacturing (Thailand) PCL Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 722.93 722.93 722.93 722.93 722.93
BKK:JSP-R
82GF Score
JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP-R
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JSP Pharmaceutical Manufacturing (Thailand) PCL Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of ฿722.9 Mil mean?
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) has a Additional Paid-In Capital of ฿722.9 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's Additional Paid-In Capital too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current Additional Paid-In Capital is ฿722.9 Mil. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's Additional Paid-In Capital compare to KHC and GIS?
JSP Pharmaceutical Manufacturing (Thailand) PCL's Additional Paid-In Capital of ฿722.9 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Consumer Packaged Goods company?
A good Additional Paid-In Capital depends on the Consumer Packaged Goods industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. JSP Pharmaceutical Manufacturing (Thailand) PCL's current Additional Paid-In Capital is ฿722.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.18, compared to a current price of ฿1.75 — trading 19.9% below its estimated fair value. The current Additional Paid-In Capital is ฿722.9 Mil. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R), the current Additional Paid-In Capital is ฿722.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Overvalued in 2026?

Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued. The current stock price of ฿1.75 is trading 19.9% below its estimated GF Value™ of ฿2.18. GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Modestly Undervalued.

Key valuation signals for BKK:JSP-R:

  • Additional Paid-In Capital: ฿722.9 Mil
  • GF Value™: ฿2.18 vs. price of ฿1.75 (19.9% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the BKK:JSP-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description

Other Exchanges JSP:Thailand
Address No. 255, 257 Soi Sathupradit 58, Bang Pongphang, Yan Nawa, Bangkok, THA, 10120
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score

Get the complete analysis for BKK:JSP-R

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿1.75
Price
฿2.18
GF Value